Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use ...

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE ...

Eversense 365 is the world’s first One Year CGM system, representing a significant breakthrough in diabetes technology and management. “The approval of Eversense 365 represents a significant ...